Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros











Base de dados
Intervalo de ano de publicação
1.
Ginecol Obstet Mex ; 81(10): 593-601, 2013 Oct.
Artigo em Espanhol | MEDLINE | ID: mdl-24483042

RESUMO

BACKGROUND: Hormone replacement therapy (HRT) with tibolone used in the management of menopause has low rates of acceptance and compliance in the first year. Few studies analyze the reasons for abandoning the use of tibolone. OBJECTIVE: To analyze the reasons for abandoned tibolone hormone replacement therapy in postmenopausal women and the effects of the drug through the years in the treatment. MATERIAL AND METHODS: In a cross-sectional study, were included 261 menopausal women between 40 and 60 year old who attended their disease control at the Gynaecological Endocrinology serving in the National Medical Center Northwest in Obregon City, Sonora, Mexico during 2010-2011. The variables studied included: age, type of menopause, time of use of HRT with tibolone, abandonment reason, development of hypertension, dyslipidemia, hypothyroidism and diabetes mellitus. RESULTS: A total of 21 women discontinued treatment (8.60%, 95% CI -3 to 19), p=0.0001. The reasons for abandonment included, 42.9% gynecological reasons (23.8% breast disease, 14.3% and 4.8% cervical condition ovarian pathology, p=0.0001). Liver disease and vascular occurred in 28.6%, p=0.050. CONCLUSION: The women studied have adequate adherence to treatment with tibolone (>90%). We don't show an increased risk of cardiovascular or metabolic disease in women studied. Further studies are needed to explore the long-term clinical course, therapeutic response and complications in menopausal patients who use HRT with tibolone.


Assuntos
Moduladores de Receptor Estrogênico/uso terapêutico , Adesão à Medicação , Menopausa , Norpregnenos/uso terapêutico , Adulto , Estudos Transversais , Moduladores de Receptor Estrogênico/administração & dosagem , Moduladores de Receptor Estrogênico/efeitos adversos , Terapia de Reposição de Estrogênios/métodos , Feminino , Humanos , México , Pessoa de Meia-Idade , Norpregnenos/administração & dosagem , Norpregnenos/efeitos adversos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA